IPK

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

Retrieved on: 
Tuesday, February 13, 2024

Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “2023 has been a transformational year for Sosei Group and the progress made by our teams across all areas of the business has been exceptional.
  • Marketing approval for PIVLAZ® in South Korea – for the prevention of cerebral vasospasm and related conditions after aneurysmal subarachnoid hemorrhage (“aSAH”) securing.
  • A Phase 1 study of NBI-1117569 has begun and a Phase 1 study of NBI-1117567 is expected to begin in 2024.

Sosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South Korea

Retrieved on: 
Thursday, December 7, 2023

Tokyo, Japan, Seoul, South Korea, and Cambridge, UK, 7 December 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) today announces that PIVLAZ™ (clazosentan sodium) 150 mg has received marketing approval from the Ministry of Food and Drug Safety (MFDS) in South Korea for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH) securing.

Key Points: 
  • Tokyo, Japan, Seoul, South Korea, and Cambridge, UK, 7 December 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) today announces that PIVLAZ™ (clazosentan sodium) 150 mg has received marketing approval from the Ministry of Food and Drug Safety (MFDS) in South Korea for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH) securing.
  • The MFDS approval is based on scientific and clinical data from an extensive Japanese Phase 3 program submitted by Idorsia Pharmaceuticals Korea (“IPK”), a Sosei Group company.
  • In South Korea, the Marketing Authorization of PIVLAZ™ is held by IPK and will become commercially available to patients in early 2025.
  • PIVLAZ™ received marketing approval in Japan in January 2022 and was launched in April 2022 by Idorsia Pharmaceuticals Japan ("IPJ”), also a Sosei Group company.

Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company

Retrieved on: 
Thursday, July 20, 2023

This fully funded transaction is truly transformational and achieves one of our key strategic objectives, establishing the Company as a fully integrated Japan-focused biopharmaceutical business, with growing commercial sales and an expected new product launch next year.

Key Points: 
  • This fully funded transaction is truly transformational and achieves one of our key strategic objectives, establishing the Company as a fully integrated Japan-focused biopharmaceutical business, with growing commercial sales and an expected new product launch next year.
  • “The Japan pharmaceutical market, given its size, large ageing population and attractive high quality clinical development and regulatory environment is the key next step for Sosei Heptares’ growth ambitions.
  • I would also like to welcome Dr. Satoshi Tanaka and the other members of the IPJ and IPK teams to Sosei Heptares.
  • The acquisition of IPJ and IPK addresses this objective and is the conclusion of a rigorous global search by the Sosei Heptares team.

ANSA MOTOR SPORTS LLC - Announces Collaboration with IPK Factory Italy Officially Becomes the Exclusive USA Importer and Factory Race Team for Formula K and OK1 Competition Karts

Retrieved on: 
Wednesday, January 4, 2023

Ansa Karting proudly becomes the USA official and exclusive importer for the Formula K and OK1.

Key Points: 
  • Ansa Karting proudly becomes the USA official and exclusive importer for the Formula K and OK1.
  • Co-owner and Ansa Karting owner Patrick-Otto Madsen stated, "We are very pleased and grateful to become the USA's sole and exclusive Importer for Formula K and OK1 chassis brands.
  • The partnership with the IPK Factory Italy and Ansa Karting leverages the opportunity to help both companies grow and support the brand development.
  • As the official importer, Ansa Karting will also become the IPK Factory supported team in the USA."

The Global Transdermal Patch Market is Expected to Reach $20 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 16, 2022

The "Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.
  • The promising response of transdermal patches in the global market has further surged the further research and development in this sector.
  • As per our report findings, the global transdermal patch market is expected to surpass US$ 20 Billion by 2028.
  • Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2028 Report Highlights:
    Clinical Trials Insight By Company, Indication, Drug Molecule & Phase
    6.

AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia

Retrieved on: 
Monday, November 22, 2021

Study AB18001 is titled A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous of AB8939 in patients with Relapsed/Refractory Acute Myeloid Leukemia.

Key Points: 
  • Study AB18001 is titled A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous of AB8939 in patients with Relapsed/Refractory Acute Myeloid Leukemia.
  • This dose expansion study aims to determine the schedule for a Phase 2 trial in patients with relapsed/refractory AML and to also provide an early efficacy (response rate) assessment of AB8939.
  • The first indication AB8939 is being developed for is acute myeloid leukemia (AML).
  • Moreover, while azacytidine was associated with strong treatment related hematotoxicity, AB8939 did not induce hematotoxicity throughout its 4-week treatment period.

Indian Pueblo Cultural Center's New Hot Air Balloon, Eyahne on the Horizon, Will Take to the Skies for Its First Albuquerque International Balloon Fiesta

Retrieved on: 
Wednesday, September 29, 2021

ALBUQUERQUE, N.M., Sept. 29, 2021 /PRNewswire-PRWeb/ -- The Indian Pueblo Cultural Center's new hot air balloon, Eyahne On The Horizon, will take to the skies for its first Albuquerque International Balloon Fiesta, which takes place Oct. 2-10, 2021.

Key Points: 
  • ALBUQUERQUE, N.M., Sept. 29, 2021 /PRNewswire-PRWeb/ -- The Indian Pueblo Cultural Center's new hot air balloon, Eyahne On The Horizon, will take to the skies for its first Albuquerque International Balloon Fiesta, which takes place Oct. 2-10, 2021.
  • The balloon made its maiden voyage in Albuquerque in September 2020 and serves as a proud ambassador for the Indian Pueblo Cultural Center (IPCC).
  • "We took delivery of our balloon in 2020 and had planned for last year's Balloon Fiesta to be Eyahne's first.
  • The Indian Pueblo Cultural Center is located at 2401 12th Street NW, just north of I-40 in Albuquerque.